Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Clin Cancer Res. 2010 May 11;16(10):2861–2871. doi: 10.1158/1078-0432.CCR-10-0569

Figure 4. Increased frequency of CD4+ ICOShi T cells is detected after patients with metastatic melanoma are treated with anti-CTLA-4.

Figure 4

A representative dot plot of ICOS staining in a melanoma patient at baseline and after anti-CTLA-4 therapy, as well as the mouse IgG1 isotype control (A). All samples analyzed for % CD4+ICOShi expression in the different donor and patient groups at different time points (B) (HD, healthy donor; Mel-Pt, control melanoma patients; Pre-tx, pre-treatment; SAV, streptavidin).